Eli Lilly’s New Products Portfolio in 3Q17

Eli Lilly and Company’s (LLY) product portfolio includes Basaglar, Jardiance, Cyramza, Lartruvo, Taltz, Olumiant, and Trulicity.

The above chart shows revenues for new products over the last eight quarters.

Trulicity reported revenues of $528 million in 3Q17, a 117% growth compared to $244 million in 3Q16. US sales were $413 million, while international sales were $115 million.

Cyramza, an oncology drug approved for the treatment of various forms of cancer, reported revenues of $196 million in 3Q17. That was a 23% growth compared to 3Q16. Growth was driven by an increase of 4% in US sales and an increase of 38% in international sales.

Taltz reported revenues of $151 million in 3Q17 compared to $33 million in 3Q16. US sales were $131 million, and international sales were $20 million.

Basaglar, an insulin glargine injection for patients with Type 1 and Type 2 diabetes, reported revenues of $145.7 million in 3Q17 compared to $19.4 million in 3Q16. Growth was driven by an increase in US sales to $115 million and an increase in international sales to $31 million.

Jardiance, which is part of the Boehringer Ingelheim and Eli Lilly diabetes alliance, reported revenues of $127 million in 3Q17. Growth was driven by an increase of $51 million in US sales and an increase of $29 million in international sales.

Lartruvo, a drug approved for the treatment of advanced soft tissue sarcoma, reported revenues of $54 million in 3Q17. US sales were $42 million, and international sales were $12 million.

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) holds 3.9% of its total investments in Eli Lilly (LLY), 7.7% in Pfizer (PFE), 3.9% in Merck & Co. (MRK), and 4.4% in Mylan (MYL).